Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc. AGRX

Alternate Symbol(s):  AGXRW

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.


Recent & Breaking News (NDAQ:AGRX)

Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2022

Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022

GlobeNewswire July 28, 2022

Agile Therapeutics Updates Second Quarter 2022 Guidance

GlobeNewswire July 12, 2022

Agile Therapeutics to Participate in Maxim Group's Upcoming Women's Health Panel

GlobeNewswire July 8, 2022

Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering

GlobeNewswire July 6, 2022

Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering

GlobeNewswire July 1, 2022

Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

GlobeNewswire May 5, 2022

Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022

GlobeNewswire May 3, 2022

Agile Therapeutics Announces 1-For-40 Reverse Stock Split

GlobeNewswire April 26, 2022

Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®

GlobeNewswire April 14, 2022

Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program

GlobeNewswire April 11, 2022

Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)

GlobeNewswire April 7, 2022

Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z

GlobeNewswire March 31, 2022

Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 30, 2022

Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering

GlobeNewswire March 14, 2022

Agile Therapeutics Announces $4.85 Million Registered Direct Offering

GlobeNewswire March 14, 2022

Agile Therapeutics to Participate in Upcoming March Investor Events

GlobeNewswire March 11, 2022